2021 -- H 5249 | |
======== | |
LC000330 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2021 | |
____________ | |
A N A C T | |
RELATING TO HEALTH AND SAFETY -- WHOLESALE PRESCRIPTION DRUG | |
IMPORTATION PROGRAM | |
| |
Introduced By: Representatives Williams, Vella-Wilkinson, Alzate, Morales, Biah, | |
Date Introduced: January 29, 2021 | |
Referred To: House Health & Human Services | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Title 23 of the General Laws entitled "HEALTH AND SAFETY" is hereby |
2 | amended by adding thereto the following chapter: |
3 | CHAPTER 95 |
4 | WHOLESALE PRESCRIPTION DRUG IMPORTATION PROGRAM |
5 | 23-95-1. Short title. |
6 | This chapter shall be known and may be cited as the "Wholesale Prescription Drug |
7 | Importation Program." |
8 | 23-95-2. Establishment of program. |
9 | The wholesale prescription drug importation program, referred to in this chapter as the |
10 | "program," is established to provide for the wholesale importation of prescription drugs from |
11 | Canada by or on behalf of the state. The program must be designed in accordance with the |
12 | requirements of this chapter. The program may not be implemented unless the state obtains |
13 | approval and certification, pursuant to § 23-95-3(c), from the U.S. Department of Health and |
14 | Human Services. |
15 | 23-95-3. Design of program. |
16 | (a) The department of health, in consultation with appropriate federal and other state |
17 | agencies, other states and interested parties, shall design the program to comply with the applicable |
18 | requirements of 21 U.S.C. § 384, including requirements regarding safety and cost savings. The |
| |
1 | program design must: |
2 | (1) Designate a state agency to become a licensed drug wholesaler or to contract with a |
3 | licensed drug wholesaler in order to seek federal certification and approval, pursuant to subsection |
4 | (c) of this section, to import safe prescription drugs and provide cost savings to consumers in the |
5 | state; |
6 | (2) Use prescription drug suppliers in Canada regulated under the laws of Canada or of one |
7 | or more Canadian Provinces, or both; |
8 | (3) Ensure that only prescription drugs meeting the U.S. Food and Drug Administration's |
9 | safety, effectiveness and other standards are imported by or on behalf of the state; |
10 | (4) Import only those prescription drugs expected to generate substantial cost savings for |
11 | consumers in the state; |
12 | (5) Ensure that the program complies with the transaction and tracing requirements of 21 |
13 | U.S.C. §§ 360eee and 360eee-1 to the extent feasible, and practical prior to imported prescription |
14 | drugs coming into the possession of the licensed drug wholesaler and that the program complies |
15 | fully with those federal requirements after imported prescription drugs are in the possession of the |
16 | licensed drug wholesaler; |
17 | (6) Consider whether the program may be developed on a multistate basis through |
18 | collaboration with other states; |
19 | (7) Prohibit the distribution, dispensing or sale of imported prescription drugs outside of |
20 | the state; |
21 | (8) Recommend a charge per prescription or another method of financing to ensure that the |
22 | program is adequately funded in a manner that does not jeopardize significant cost savings to |
23 | consumers, including adequate funding for the initial startup costs of the program; |
24 | (9) Apply for and receive funds, grants or contracts from public and private sources; and |
25 | (10) Include an audit function. |
26 | (b) Rules and regulations. The department of health shall promulgate rules and regulations |
27 | to design the program in accordance with the requirements of subsection (a) of this section no later |
28 | than January 1, 2022. |
29 | (c) Request for federal approval and certification. The department of health shall submit a |
30 | request for approval and certification of the Program to the U.S. Department of Health and Human |
31 | Services no later than May 1, 2022. |
32 | 23-95-4. Implementation and operation. |
33 | (a) Upon receipt of federal approval and certification under § 23-95-3(c), the state agency |
34 | designated to oversee the program pursuant to this chapter shall implement the program as required |
| LC000330 - Page 2 of 5 |
1 | in subsection (b) of this section. The program must begin operating no later than six (6) months |
2 | following receipt of federal approval and certification. |
3 | (b) Requirements. Prior to operating the program, the state agency designated to oversee |
4 | the program pursuant to this chapter shall: |
5 | (1) Become a licensed drug wholesaler or enter into a contract with a licensed drug |
6 | wholesaler in the state; |
7 | (2) Contract with one or more distributors licensed in the state; |
8 | (3) Contract with one or more licensed and regulated prescription drug suppliers in Canada; |
9 | (4) Consult with health insurance carriers, employers, pharmacies, pharmacists, health care |
10 | providers and consumers; |
11 | (5) Develop a registration process for health insurance carriers, pharmacies and health care |
12 | providers authorized to prescribe and administer prescription drug that are willing to participate in |
13 | the program; |
14 | (6) Create a publicly accessible website for listing the prices of prescription drugs to be |
15 | imported under the program; |
16 | (7) Create an outreach and marketing plan to generate public awareness of the program; |
17 | (8) Provide a telephone hotline to answer questions and address needs of consumers, |
18 | employers, health insurance carriers, pharmacies, health care providers and others affected by the |
19 | program; |
20 | (9) Develop a two (2) year audit work plan; and |
21 | (10) Conduct any other activity determined necessary to successfully implement and |
22 | operate the program. |
23 | 23-95-5. Annual reporting. |
24 | Beginning January 2023, and annually. thereafter, the department of health, or other state |
25 | agency designated to oversee the program pursuant to this chapter, shall report to the speaker of |
26 | the house of representatives and the president of the senate regarding the implementation and |
27 | operation of the program during the previous calendar year, including: |
28 | (1) The prescription drugs included in the program; |
29 | (2) The number of participating pharmacies, health care providers and health insurance |
30 | carriers; |
31 | (3) The number of prescription drugs dispensed through the program; |
32 | (4) The estimated cost savings to consumers, health insurance carriers, employers and the |
33 | state during the previous calendar year and to date; |
34 | (5) Information regarding implementation of the audit work plan and audit finding; and |
| LC000330 - Page 3 of 5 |
1 | (6) Any other information the department of health, or other state agency designated to |
2 | oversee the program pursuant to this chapter, considers relevant. |
3 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC000330 | |
======== | |
| LC000330 - Page 4 of 5 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO HEALTH AND SAFETY -- WHOLESALE PRESCRIPTION DRUG | |
IMPORTATION PROGRAM | |
*** | |
1 | This act would establish a program for the importation of wholesale prescription drugs |
2 | from Canada to provide cost savings to Rhode Island consumers. |
3 | This act would take effect upon passage. |
======== | |
LC000330 | |
======== | |
| LC000330 - Page 5 of 5 |